



## **Terns Pharmaceuticals to Present at Upcoming Investor Conferences**

August 3, 2021

FOSTER CITY, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, today announced that management will be participating in a liver disease panel at the 2021 Wedbush PacGrow Healthcare Conference on Tuesday, August 10 at 2:20pm ET. Terns management will also present at the Canaccord Genuity 41<sup>st</sup> Annual Growth Conference on Wednesday, August 11 at 1:00pm ET.

A live webcast of the events will be available on the investor relations page of the Terns Pharmaceuticals website at <http://ir.ternspharma.com>. A replay of the webcasts will be archived on Terns' website for 30 days following the presentations.

### **About Terns Pharmaceuticals**

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. Terns' pipeline includes three clinical stage development programs including an FXR agonist, a VAP-1 inhibitor and a THR- $\beta$  agonist, and a preclinical GLP-1 receptor agonist program. Terns is focused on developing combination therapies based on clinically validated and complementary mechanisms of action to address the multiple hepatic disease processes of NASH in order to drive meaningful clinical benefits for patients. For more information, please visit: [www.ternspharma.com](http://www.ternspharma.com).

Contacts for Terns Investors Justin Ng [investors@ternspharma.com](mailto:investors@ternspharma.com) Media Jenna Urban Berry & Company Public Relations [media@ternspharma.com](mailto:media@ternspharma.com)